Latest Commercialization News

PYC Therapeutics reports solid progress across its four RNA therapeutic programs targeting genetic diseases, backed by a strong cash position extending runway beyond 2027.

Loyal Metals has partnered with veteran geologist Dr. Simon Beams to unlock the untapped copper-gold potential of the historic Highway Reward Mine using advanced AI and modern exploration techniques.

Tryptamine Therapeutics has begun recruiting patients for a pioneering clinical trial testing IV-infused psilocin combined with psychotherapy to treat Binge Eating Disorder, aiming to deliver faster and more controlled treatment outcomes.

Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.

Omega Oil & Gas has secured a $7.3 million refundable R&D tax offset for FY23, bolstering its financial position and supporting ongoing development of its promising Canyon Project in Queensland.

Nanoveu Limited has completed a $2 million capital raise through a strategic placement and exercised options, reinforcing its position in advanced semiconductor and 3D visualization technologies.

Firebird Metals has secured two key patents for its proprietary Lithium Manganese Iron Phosphate (LMFP) battery materials, reinforcing its position in the emerging $20 billion LMFP market. The company’s integrated production approach and expanding IP portfolio set the stage for global growth amid shifting technology controls.

Peregrine Gold Limited has announced a major discovery of a high-grade Channel Iron Deposit spanning over 7.7km near key BHP iron ore operations in Western Australia. Initial assays reveal iron grades averaging 57%, highlighting significant potential for the Newman Gold Project.

Yowie Group has arranged a $1 million short-term funding facility from parent Keybridge Capital to manage cash flow while investigating former directors' use of funds and intra-group loans.

Connexion Mobility reported steady revenue growth and a 7% increase in net profit before tax for Q4 FY25, driven by expanding SaaS subscriptions and strategic product enhancements.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.

4DMedical has renewed its three-year contract with the University of Michigan Medical Center, reinforcing its foothold in US respiratory imaging. Alongside, a pivotal clinical study validates its technology’s ability to detect early lung disease, while a substantial Australian grant boosts its AI research.